Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
European Journal of Cancer2004Vol. 40(5), pp. 689–695
Citations Over TimeTop 1% of 2004 papers
Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson, Bartosz Wasąg, Jaap Verweij, Matthew F. Brown, Saša Dimitrijević, Raf Sciot, Michel Stul, H. Vranck, Michelle Scurr, A Hagemeijer, M. van Glabbeke, A.T. van Oosterom
Related Papers
- → Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors(2017)32 cited
- → Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)(2015)25 cited
- → Avapritinib in the Treatment of PDGFRA Exon 18 Mutated Gastrointestinal Stromal Tumors(2020)15 cited
- → Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study(2011)34 cited
- c-kit and PDGFRA gene mutation in gastrointestinal stromal tumors and its significance(2008)